TREATMENT OF PATIENTS DIAGNOSED WITH PANCREATIC DUCTAL ADENOCARCINOMA USING USING MONOCLONAL ANTIBODIES AGAINST THE EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR)
Dirk STRUMBERG,Beate SCHULTHEIS,Matthias P. EBERT,Jens SIVEKE,Andrea KERKHOFF,Ralf HOFHEINZ,Dirk M. BEHRINGER,Wolfgang E. SCHMIDT,Erdem GOKER,Sara DE DOSSO,Michael KNEBA,Suayib YALCIN,Friedrich OVERKA
申请号：
US15748173
公开号：
US20180221478A1
申请日:
2016.07.27
申请国别(地区):
US
年份:
2018
代理人:
摘要：
The present disclosure relates to the field of immunotherapy of cancer, in particular pancreatic ductal adenocarcinoma (PDAC). Means and methods for treatment of a population of PDAC patients suffering from PDAC tumours which express wildtype KRAS, HRAS or NRAS are disclosed. The claimed antibody is Nimotuzumab. The pancreatic cancer preferably does not contain KRAS mutations at position 12, 16, 61, 154.
